Pharmacy

Dec 25 2017

Patheon and DSM complete $ merger to form private company DPx #pharmaceutical #industry #marketing

#dsm pharma # Patheon and DSM complete $2.65bn merger to form private company ‘DPx’ By Dan Stanton+ Dan Stanton 12-Mar-2014 2014-03-12T00:00:00Z Last updated on 12-Mar-2014 at 09:49 GMT 2014-03-12T09:49:12Z Patheon has merged with Royal DSM’s pharmaceutical products business to form DPx in a $2.65bn (€1.9bn) deal that analysts believe has created the world’s second biggest CMO. Plans for the merger were announced in November last year, but the deal only completed yesterday. Under the new structure Patheon’s owner JLL Holdings has a 51% share in DPx with Royal DSM who controlling the remaining 49%. The new company will consist of …

Dec 18 2017

Patheon and DSM complete $ merger to form private company DPx #pharma #test

#dsm pharma # Patheon and DSM complete $2.65bn merger to form private company ‘DPx’ By Dan Stanton+ Dan Stanton 12-Mar-2014 2014-03-12T00:00:00Z Last updated on 12-Mar-2014 at 09:49 GMT 2014-03-12T09:49:12Z Patheon has merged with Royal DSM’s pharmaceutical products business to form DPx in a $2.65bn (€1.9bn) deal that analysts believe has created the world’s second biggest CMO. Plans for the merger were announced in November last year, but the deal only completed yesterday. Under the new structure Patheon’s owner JLL Holdings has a 51% share in DPx with Royal DSM who controlling the remaining 49%. The new company will consist of …

Nov 30 2017

Patheon and DSM complete $ merger to form private company DPx #novartis #pharma

#dsm pharma # Patheon and DSM complete $2.65bn merger to form private company ‘DPx’ By Dan Stanton+ Dan Stanton 12-Mar-2014 2014-03-12T00:00:00Z Last updated on 12-Mar-2014 at 09:49 GMT 2014-03-12T09:49:12Z Patheon has merged with Royal DSM’s pharmaceutical products business to form DPx in a $2.65bn (€1.9bn) deal that analysts believe has created the world’s second biggest CMO. Plans for the merger were announced in November last year, but the deal only completed yesterday. Under the new structure Patheon’s owner JLL Holdings has a 51% share in DPx with Royal DSM who controlling the remaining 49%. The new company will consist of …

Nov 14 2017

Patheon and DSM complete $ merger to form private company DPx #orbus #pharma

#dsm pharma # Patheon and DSM complete $2.65bn merger to form private company ‘DPx’ By Dan Stanton+ Dan Stanton 12-Mar-2014 2014-03-12T00:00:00Z Last updated on 12-Mar-2014 at 09:49 GMT 2014-03-12T09:49:12Z Patheon has merged with Royal DSM’s pharmaceutical products business to form DPx in a $2.65bn (€1.9bn) deal that analysts believe has created the world’s second biggest CMO. Plans for the merger were announced in November last year, but the deal only completed yesterday. Under the new structure Patheon’s owner JLL Holdings has a 51% share in DPx with Royal DSM who controlling the remaining 49%. The new company will consist of …

Sep 1 2017

Patheon Reaches Agreement With BSP Pharmaceuticals for Development and Manufacture of Cytotoxics #pharmical #companies

#bsp pharma # Patheon Reaches Agreement With BSP Pharmaceuticals for Development and Manufacture of Cytotoxics TORONTO, July 2 /PRNewswire/ — Patheon (TSX:PTI), a global provider of drug development and manufacturing services to the international pharmaceutical industry, has completed a shareholders agreement and a sales and marketing agreement with Italy’s BSP Pharmaceuticals, a company focussed on the development and manufacturing of cytotoxic pharmaceutical products. Under the terms of the sales and marketing agreement, Patheon will promote BSP’s cytotoxic manufacturing capacity and development services. Mr. Aldo Braca, President, Patheon Europe will be President and Chief Executive Officer of BSP Pharmaceuticals. Patheon is …

Aug 25 2017

Patheon and DSM complete $ merger to form private company DPx #dainippon #sumitomo #pharma

#dsm pharma # Patheon and DSM complete $2.65bn merger to form private company ‘DPx’ By Dan Stanton+ Dan Stanton 12-Mar-2014 2014-03-12T00:00:00Z Last updated on 12-Mar-2014 at 09:49 GMT 2014-03-12T09:49:12Z Patheon has merged with Royal DSM’s pharmaceutical products business to form DPx in a $2.65bn (€1.9bn) deal that analysts believe has created the world’s second biggest CMO. Plans for the merger were announced in November last year, but the deal only completed yesterday. Under the new structure Patheon’s owner JLL Holdings has a 51% share in DPx with Royal DSM who controlling the remaining 49%. The new company will consist of …

Mar 31 2017

Patheon and DSM complete $ merger to form private company DPx #pharma #magazine

#dsm pharma # Patheon and DSM complete $2.65bn merger to form private company ‘DPx’ By Dan Stanton+ Dan Stanton 12-Mar-2014 2014-03-12T00:00:00Z Last updated on 12-Mar-2014 at 09:49 GMT 2014-03-12T09:49:12Z Patheon has merged with Royal DSM’s pharmaceutical products business to form DPx in a $2.65bn (€1.9bn) deal that analysts believe has created the world’s second biggest CMO. Plans for the merger were announced in November last year, but the deal only completed yesterday. Under the new structure Patheon’s owner JLL Holdings has a 51% share in DPx with Royal DSM who controlling the remaining 49%. The new company will consist of …

Mar 27 2017

Patheon Reaches Agreement With BSP Pharmaceuticals for Development and Manufacture of Cytotoxics #big #pharmaceutical #companies

#bsp pharma # Patheon Reaches Agreement With BSP Pharmaceuticals for Development and Manufacture of Cytotoxics TORONTO, July 2 /PRNewswire/ — Patheon (TSX:PTI), a global provider of drug development and manufacturing services to the international pharmaceutical industry, has completed a shareholders agreement and a sales and marketing agreement with Italy’s BSP Pharmaceuticals, a company focussed on the development and manufacturing of cytotoxic pharmaceutical products. Under the terms of the sales and marketing agreement, Patheon will promote BSP’s cytotoxic manufacturing capacity and development services. Mr. Aldo Braca, President, Patheon Europe will be President and Chief Executive Officer of BSP Pharmaceuticals. Patheon is …

Feb 9 2017

Patheon Reaches Agreement With BSP Pharmaceuticals for Development and Manufacture of Cytotoxics #aristo #pharma

#bsp pharma # Patheon Reaches Agreement With BSP Pharmaceuticals for Development and Manufacture of Cytotoxics TORONTO, July 2 /PRNewswire/ — Patheon (TSX:PTI), a global provider of drug development and manufacturing services to the international pharmaceutical industry, has completed a shareholders agreement and a sales and marketing agreement with Italy’s BSP Pharmaceuticals, a company focussed on the development and manufacturing of cytotoxic pharmaceutical products. Under the terms of the sales and marketing agreement, Patheon will promote BSP’s cytotoxic manufacturing capacity and development services. Mr. Aldo Braca, President, Patheon Europe will be President and Chief Executive Officer of BSP Pharmaceuticals. Patheon is …

Jan 30 2017

Patheon and DSM complete $ merger to form private company DPx #abbott #pharma

#dsm pharma # Patheon and DSM complete $2.65bn merger to form private company ‘DPx’ By Dan Stanton+ Dan Stanton 12-Mar-2014 2014-03-12T00:00:00Z Last updated on 12-Mar-2014 at 09:49 GMT 2014-03-12T09:49:12Z Patheon has merged with Royal DSM’s pharmaceutical products business to form DPx in a $2.65bn (€1.9bn) deal that analysts believe has created the world’s second biggest CMO. Plans for the merger were announced in November last year, but the deal only completed yesterday. Under the new structure Patheon’s owner JLL Holdings has a 51% share in DPx with Royal DSM who controlling the remaining 49%. The new company will consist of …

Jan 18 2017

Patheon Reaches Agreement With BSP Pharmaceuticals for Development and Manufacture of Cytotoxics #top #20 #pharma

#bsp pharma # Patheon Reaches Agreement With BSP Pharmaceuticals for Development and Manufacture of Cytotoxics TORONTO, July 2 /PRNewswire/ — Patheon (TSX:PTI), a global provider of drug development and manufacturing services to the international pharmaceutical industry, has completed a shareholders agreement and a sales and marketing agreement with Italy’s BSP Pharmaceuticals, a company focussed on the development and manufacturing of cytotoxic pharmaceutical products. Under the terms of the sales and marketing agreement, Patheon will promote BSP’s cytotoxic manufacturing capacity and development services. Mr. Aldo Braca, President, Patheon Europe will be President and Chief Executive Officer of BSP Pharmaceuticals. Patheon is …

Dec 9 2016

Patheon and DSM complete $ merger to form private company DPx #gmp #pharma

#dsm pharma # Patheon and DSM complete $2.65bn merger to form private company ‘DPx’ By Dan Stanton+ Dan Stanton 12-Mar-2014 2014-03-12T00:00:00Z Last updated on 12-Mar-2014 at 09:49 GMT 2014-03-12T09:49:12Z Patheon has merged with Royal DSM’s pharmaceutical products business to form DPx in a $2.65bn (€1.9bn) deal that analysts believe has created the world’s second biggest CMO. Plans for the merger were announced in November last year, but the deal only completed yesterday. Under the new structure Patheon’s owner JLL Holdings has a 51% share in DPx with Royal DSM who controlling the remaining 49%. The new company will consist of …

Nov 27 2016

Patheon Reaches Agreement With BSP Pharmaceuticals for Development and Manufacture of Cytotoxics #pharmaceutical #information

#bsp pharma # Patheon Reaches Agreement With BSP Pharmaceuticals for Development and Manufacture of Cytotoxics TORONTO, July 2 /PRNewswire/ — Patheon (TSX:PTI), a global provider of drug development and manufacturing services to the international pharmaceutical industry, has completed a shareholders agreement and a sales and marketing agreement with Italy’s BSP Pharmaceuticals, a company focussed on the development and manufacturing of cytotoxic pharmaceutical products. Under the terms of the sales and marketing agreement, Patheon will promote BSP’s cytotoxic manufacturing capacity and development services. Mr. Aldo Braca, President, Patheon Europe will be President and Chief Executive Officer of BSP Pharmaceuticals. Patheon is …

Nov 21 2016

Patheon and DSM complete $ merger to form private company DPx #cipla

#dsm pharma # Patheon and DSM complete $2.65bn merger to form private company ‘DPx’ By Dan Stanton+ Dan Stanton 12-Mar-2014 2014-03-12T00:00:00Z Last updated on 12-Mar-2014 at 09:49 GMT 2014-03-12T09:49:12Z Patheon has merged with Royal DSM’s pharmaceutical products business to form DPx in a $2.65bn (€1.9bn) deal that analysts believe has created the world’s second biggest CMO. Plans for the merger were announced in November last year, but the deal only completed yesterday. Under the new structure Patheon’s owner JLL Holdings has a 51% share in DPx with Royal DSM who controlling the remaining 49%. The new company will consist of …

Nov 17 2016

Patheon Reaches Agreement With BSP Pharmaceuticals for Development and Manufacture of Cytotoxics #thompson #pharma

#bsp pharma # Patheon Reaches Agreement With BSP Pharmaceuticals for Development and Manufacture of Cytotoxics TORONTO, July 2 /PRNewswire/ — Patheon (TSX:PTI), a global provider of drug development and manufacturing services to the international pharmaceutical industry, has completed a shareholders agreement and a sales and marketing agreement with Italy’s BSP Pharmaceuticals, a company focussed on the development and manufacturing of cytotoxic pharmaceutical products. Under the terms of the sales and marketing agreement, Patheon will promote BSP’s cytotoxic manufacturing capacity and development services. Mr. Aldo Braca, President, Patheon Europe will be President and Chief Executive Officer of BSP Pharmaceuticals. Patheon is …

Nov 9 2016

Patheon Reaches Agreement With BSP Pharmaceuticals for Development and Manufacture of Cytotoxics #pharma #marketing #strategies

#bsp pharma # Patheon Reaches Agreement With BSP Pharmaceuticals for Development and Manufacture of Cytotoxics TORONTO, July 2 /PRNewswire/ — Patheon (TSX:PTI), a global provider of drug development and manufacturing services to the international pharmaceutical industry, has completed a shareholders agreement and a sales and marketing agreement with Italy’s BSP Pharmaceuticals, a company focussed on the development and manufacturing of cytotoxic pharmaceutical products. Under the terms of the sales and marketing agreement, Patheon will promote BSP’s cytotoxic manufacturing capacity and development services. Mr. Aldo Braca, President, Patheon Europe will be President and Chief Executive Officer of BSP Pharmaceuticals. Patheon is …

Nov 3 2016

Patheon and DSM complete $ merger to form private company DPx #pharma #agency

#dsm pharma # Patheon and DSM complete $2.65bn merger to form private company ‘DPx’ By Dan Stanton+ Dan Stanton 12-Mar-2014 2014-03-12T00:00:00Z Last updated on 12-Mar-2014 at 09:49 GMT 2014-03-12T09:49:12Z Patheon has merged with Royal DSM’s pharmaceutical products business to form DPx in a $2.65bn (€1.9bn) deal that analysts believe has created the world’s second biggest CMO. Plans for the merger were announced in November last year, but the deal only completed yesterday. Under the new structure Patheon’s owner JLL Holdings has a 51% share in DPx with Royal DSM who controlling the remaining 49%. The new company will consist of …

Sep 26 2016

Patheon and DSM complete $ merger to form private company DPx

#dsm pharma # Patheon and DSM complete $2.65bn merger to form private company ‘DPx’ By Dan Stanton+ Dan Stanton 12-Mar-2014 2014-03-12T00:00:00Z Last updated on 12-Mar-2014 at 09:49 GMT 2014-03-12T09:49:12Z Patheon has merged with Royal DSM’s pharmaceutical products business to form DPx in a $2.65bn (€1.9bn) deal that analysts believe has created the world’s second biggest CMO. Plans for the merger were announced in November last year, but the deal only completed yesterday. Under the new structure Patheon’s owner JLL Holdings has a 51% share in DPx with Royal DSM who controlling the remaining 49%. The new company will consist of …

Sep 17 2016

Patheon and DSM complete $ merger to form private company DPx

#dsm pharma # Patheon and DSM complete $2.65bn merger to form private company ‘DPx’ By Dan Stanton+ Dan Stanton 12-Mar-2014 2014-03-12T00:00:00Z Last updated on 12-Mar-2014 at 09:49 GMT 2014-03-12T09:49:12Z Patheon has merged with Royal DSM’s pharmaceutical products business to form DPx in a $2.65bn (€1.9bn) deal that analysts believe has created the world’s second biggest CMO. Plans for the merger were announced in November last year, but the deal only completed yesterday. Under the new structure Patheon’s owner JLL Holdings has a 51% share in DPx with Royal DSM who controlling the remaining 49%. The new company will consist of …